Epidemiological cutoff values (ECVs) were established for the new triazole isavuconazole
and Aspergillus species wild-type (WT) MIC distributions (organisms in a species-drug …

Isavuconazole is a novel expanded-spectrum triazole, which has recently been approved by
the FDA as an orphan drug to treat invasive aspergillosis and is currently being studied in …

Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium sulfate, is a
triazole antifungal agent for the treatment of invasive fungal infections. The purpose of this …

Introduction Isavuconazole is a new triazole approved for the treatment of invasive
aspergillosis. We investigated isavuconazole MIC distributions, isavuconazole MIC …

Objective The in vitro activity of isavuconazole was determined for 1677 Candida and 958
Aspergillus isolates from 2012 to 2014 with voriconazole as comparator. Methods …

Isavuconazole is the newest medical azole. We investigated EUCAST MICs for
isavuconazole and seven comparators against 1,498 contemporary isolates (2016 to 2017) …

The interaction of isavuconazole with immunosuppressors (tacrolimus, cyclosporin A, or
sirolimus) against 30 Aspergillus isolates belonging to the most common species …

Monitoring antifungal susceptibility patterns for new and established antifungal agents
seems prudent given the increasing prevalence of uncommon species associated with …

Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of
fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya …

Triazoles compounds are first-line agents for the treatment of invasive fungal diseases.
Isavuconazole is the most recent triazole compound, approved in 2015 by the FDA and the …